Emerging Therapy for the Treatment of Mantle Cell Lymphoma

Abstract

Mantle cell lymphoma (MCL) is a heterogenous disease with historically relative poor outcomes. However, new treatment strategies seem to be improving the prognosis for patients. Although no universally accepted standard of care exists, options for patients with newly diagnosed MCL include intensive and nonintensive strategies. Generally, intensive strategies produce more durable remissions and are selected for younger patients, whereas nonintensive strategies are most appropriate for older patients or patients with comorbidities. However, new options are closing the treatment gap between intensive and nonintensive strategies. Treatment options are also increasing for patients with relapsed/refractory MCL and include agents targeting the microenvironment and the B-cell receptor signaling pathway. (J Natl Compr Canc Netw 2014;12:1311-1318

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

“…The ideal candidates for intensive strategies are patients aged 65 years or younger without significant comorbidities, while non-intensive strategies are reserved for elderly patients of more than 65 years or patients with significant comorbidities [98]. Several historical clinical trials have evaluated efficacy of various treatment regimens with respect to partial response (PR), complete response (CR), overall response rate (ORR), and OS; these have included CHOP, R-CHOP, Maxi-R-CHOP (R-CHOP followed by higher doses of cytarabine, followed by an autologous stem cell transplant); R-hyper-CVAD (Rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose cytarabine and methotrexate) with or without autologous stem cell transplantation; BR (Bendamustine and Rituximab); R-FCM (Rituximab, fludarabine, cyclophosphamide, and mitoxantrone); R-DHAP (Rituximab, dexamethasone, cytarabine and cisplatin); R-CVP (Rituximab, cyclophosphamide, vincristine, and prednisone); R-CBP (Rituximab, cyclophosphamide, bortezomib, and prednisone); R-VAD+C (Rituximab, vincristine, doxorubicin, dexamethasone, chlorambucil); and RiPAD+C (rituximab, bortezomib, doxorubicin, dexamethasone, and chlorambucil) (Table 2).…”

SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma

“…Although the mechanisms and signaling pathways of this tumorigenic event in MCL are poorly understood, [13][14][15] promising therapeutic approaches that disrupt crosstalk between the microenvironment and tumor cells to prevent the development of drug resistance and chemotherapy refractoriness are currently in early clinical development in patients with MCL. [16][17][18][19][20][21] In this study, we searched for potential SOX11 direct target genes that may explain the relationship between SOX11 and tumor microenvironment protective interactions to find new…”

Synchronous presentation of invasive ductal carcinoma and mantle cell lymphoma: a diagnostic challenge in menopausal patients

“…Of the 37 known cases of synchronous, non-Hodgkin lymphoma (NHL) and breast cancer, most exist only as case reports or small case series with limited follow-ups. Here, we present only the third reported case of synchronous, mantle cell lymphoma (MCL), a rare form of malignancy that accounts for 3–6% of NHL [ 4 ] and invasive ductal carcinoma (IDC).…”